Please ensure Javascript is enabled for purposes of website accessibility

Why Athenex Stock Skyrocketed Today

By Joe Tenebruso - May 5, 2021 at 5:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A blockbuster acquisition could help the biotech "convert cancer into a chronic disease."

What happened

Shares of Athenex (ATNX -3.33%) soared on Wednesday after the pharmaceutical company announced a game-changing merger. By the close of trading, Athenex's stock price was up 22.6% after rising as much as 55% earlier in the day. 

So what

Athenex reached a deal to buy Kuur Therapeutics, the leading developer of off-the-shelf CAR-NKT cell immunotherapies, for as much as $185 million.

"CAR-NKT cells offer a distinct set of advantages over other immune effector cells commonly used for cell therapy," Kuur CEO Kevin Boyle said in a press release. "We are excited that the leadership at Athenex recognizes the significant potential of this approach to provide effective treatment options for patients with both solid and hematological tumors."

Pawn chess pieces are surrounding a king chess piece.

Athenex and Kuur Therapeutics are joining forces to become a leader in cell therapy. Image source: Getty Images.

Kuur's shareholders will receive an up-front payment of $70 million that will be paid mostly in Athenex stock. The deal also includes up to $115 million in milestone payments.

Now what 

Kuur has several products in early-stage trials. It plans to share more data from one of its phase 1 studies at the American Society of Gene & Cell Therapy meeting on May 14.

"We are confident that we can continue to innovate on the NKT cell platform," said Dr. Dan Lang, president of Athenex Cell Therapy. "We aspire to convert cancer into a chronic disease."

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Athenex, Inc. Stock Quote
Athenex, Inc.
ATNX
$0.52 (-3.33%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.